Результаты поиска

Emerging new therapeutic antibody derivatives for cancer treatment.

Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells. The successful application of IgG monoclonal antibodies has inspired the development of various types of therapeutic antibodies, such as antibody fragments, bispecific antibodies, and antibody derivatives (e.g., antibody-drug conjugates and immunocytokines). The miniaturization and multifunctionalization of antibodies are flexible and viable strategies for diagnosing or treating malignant tumors in a complex t

Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology.

The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines

Совпадение в полном тексте источника
… Conversely, blood levels of direct oral anticoagulants, particularly the thrombin inhibitor dabigatran, rise when administered in combination with ibrutinib, thereby increasing the risk of bleeding. …

The Arrhythmic Burden of Cardiac Amyloidosis: A Comprehensive Review.

Cardiac amyloidosis (CA) represents a growing etiology of heart failure (HF) and arrhythmogenesis, driven by the intramyocardial deposition of aberrantly folded proteins, notably immunoglobulin light chains (AL) and transthyretin (ATTR). This infiltrative process compromises myocardial compliance and disrupts the cardiac conduction system, leading to a diverse spectrum of dysrhythmias. The escalating prevalence of CA, particularly within geriatric demographics and individuals with plasma cell dyscrasias, underscores the imperative for refined diagnostic and therapeutic paradigms. The considera

Совпадение в полном тексте источника
… DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) should be first-line because they have lower bleeding risks and better-predictable pharmacokinetic profiles than Vitamin K antagonists.[ 96 ] Controversies in device therapy for cardiac amyloidosis-associated arrhythmias Device therapy in CA poses …

From Selection to Use: Aptamers as Targeting Reagents in Hematology.

Aptamers are synthetic nucleic acid ligands that have been proposed as alternatives to antibodies for targeting molecules and cells. In hematology, most reviews have organized aptamer literature around diseases or technological platforms. This framing has obscured how unevenly different blood cell types have been covered. In this review, we present developed aptamers organized by blood cell lineages. Specifically, we examine aptamers for B cells, T cells, natural killer cells, and red blood cells. This organization revealed a strong concentration on a small set of canonical surface markers and

Совпадение в полном тексте источника
… More recently, Sullenger and coworkers introduced an “EXACT” (Exosite–ACTive site) anticoagulant in which a thrombin exosite-binding aptamer was chemically conjugated to dabigatran, a small-molecule active-site inhibitor [ 172 ]. …

Artificial Intelligence Resources for the Screening of Titles and Abstracts in Systematic Reviews: A Scoping Review.

IntroductionArtificial intelligence (AI) is a branch of technology enabling machines to emulate complex human skills; it can also entail problem-solving using bioinspired methods. It is used for automating systematic literature reviews (SLR), that is, defining a clinical question, locating relevant literature, preliminary screening, study evaluation, data extraction and analysis. Title and abstract screening is one of the most time-consuming and error-prone phases involved in developing a systematic review. While AI promises to expedite this process, adopting it faces challenges due to concern

Совпадение в полном тексте источника
… Lange | Germany | 2021 | Naive Bayes, L2‐Logistic regression, C5‐0, random forest (RF), SVM, multilayer perceptron, convolutional neural network, soft voting, stacking | Orthopaedics [ 99 ] | Tsou | USA | 2020 | Abstrackr, EPPI‐Reviewer | Pancreatic cancer, Indoor allergen reduction, Inguinal hernia, Dabigatran …

49th ESCP virtual symposium on clinical pharmacy 19.10.2021-21.10.2021 Clinical pharmacy, working collaboratively in mental health care.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.

Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.

Transparent and accurate reporting in early phase dose-finding (EPDF) clinical trials is crucial for informing subsequent larger trials. The SPIRIT statement, designed for trial protocol content, does not adequately cover the distinctive features of EPDF trials. Recent findings indicate that the protocol contents in past EPDF trials frequently lacked completeness and clarity. To address this gap, the international consensus-driven SPIRIT-DEFINE checklist was developed through a robust methodological framework for guideline development, with the aim to improve completeness and clarity in EPDF t

Совпадение в полном тексте источника
… More recently, several direct-acting oral anticoagulants (DOACs) (e.g, apixaban, rivaroxaban, dabigatran, edoxaban) have been approved for use in TKR, based on comparisons with the low molecular-weight heparin (LMWH), enoxaparin, and their use has become more widespread in this patient population. …

Abstracts - IANCON 2025

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care : 19–21 October 2022, Prague, Czech Republic

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design.

Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy of standard treatment methods is insufficient and results in treatment failure and reduced patient survival. CTCs are seen not only as an isolated phenomenon but also a key inherent part of the formation of metastasis and a key factor in cancer death.

Proceedings of the RAMI Intern Section Meeting.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Rivaroxaban was the most common OAC prescribed (47.5%), followed by warfarin (28.5%), dabigatran (19%) and apixiban (5%). Upper and lower GIBs represented 45.7% and 43.4% of the total, respectively, with 10.9% remaining unclear in origin. …

SEDCYDO - SGER - SEMO ConГРЕСС МАДРИД 2025, 8-10 Возможно. Ход работы и резюме.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts - IANCON 2024

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Standard Poster Abstracts for the 17th Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Methods: We systematically searched Pubmed, Scopus, and Cochrane Library for Randomized Controlled Trials (RCT) that compare the efficacy and/or safety of DOAC (edoxaban, apixaban, dabigatran, or rivaroxaban) with VKA (warfarin or other VKAs) in AF patients with moderate CKD (CrCl 30‐50 mL/min), advanced …

UEG Week 2015 Poster Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Неделя ГЭЭ 2017 Презентации на плакате

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ИАНКОН 2023 Выдержки из плаката

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts from the World Congress of Cardiology/Brazilian Congress of Cardiology 2022

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

UEG Week 2017 Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.